Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 20/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | RARG | P13631 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2085167 | 0.92 | GCK (0.53) | GCKKCNH2RARG | |
| SCHEMBL2087542 | 0.91 | GCK (0.48) | GCKKCNH2RARG | |
| SCHEMBL2668079 | 0.91 | GCK (0.48) | GCKKCNH2RARG | |
| SCHEMBL2086661 | 0.91 | GCK (0.51) | GCKKCNH2RARG | |
| SCHEMBL2668044 | 0.91 | GCK (0.51) | GCKKCNH2RARG | |
| SCHEMBL2085618 | 0.90 | GCK (0.47) | GCK | |
| SCHEMBL2087575 | 0.90 | GCK (0.48) | GCKKCNH2RARG | |
| SCHEMBL2086003 | 0.89 | GCK (0.70) | GCKRARG | |
| SCHEMBL9072503 | 0.89 | GCK (0.70) | GCKRARG | |
| SCHEMBL2086481 | 0.89 | GCK (0.46) | GCKKCNH2RARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059941-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4,5B] PYRIDINE/PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2011-03-10 | — | — | US | claimed |
| US-20110059941-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4,5B] PYRIDINE/PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2011-03-10 | — | — | US | disclosed |
| US-20110059941-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4,5B] PYRIDINE/PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2011-03-10 | — | — | US | disclosed |
| US-20110059941-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4,5B] PYRIDINE/PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2011-03-10 | — | — | US | disclosed |
| WO-2006125958-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4 , 5B] PYRIDINE/ PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059941-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4,5B] PYRIDINE/PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | GCK, PDXK, GCKR | GCK 1/4885KCNH2 438/4885RARG 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.